普利制药(300630) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 373,166,292.20, an increase of 1.42% compared to CNY 367,925,505.63 in the same period last year[5] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 128,887,445.84, down 13.28% from CNY 148,627,173.03 in the previous year[5] - Total operating revenue for the current period reached ¥373,166,292.20, an increase from ¥367,925,505.63 in the previous period, representing a growth of approximately 0.66%[32] - Net profit for the current period was ¥138,433,086.41, down from ¥161,777,968.14, indicating a decrease of approximately 14.39%[34] - The total comprehensive income attributable to the parent company's owners was approximately $138.43 million, down from $161.78 million in the previous period, representing a decrease of about 14.4%[49] - Basic and diluted earnings per share were both $0.32, compared to $0.37 in the previous period, reflecting a decline of approximately 13.5%[49] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the same period last year[5] - Cash inflow from operating activities totaled approximately $446.38 million, an increase of about 25% from $357.66 million in the previous period[49] - Cash outflow from operating activities was approximately $417.60 million, up from $335.38 million, indicating an increase of about 24.5%[49] - The net cash flow from operating activities was approximately $28.78 million, an increase of about 29.5% compared to $22.28 million in the previous period[49] - Cash outflow from investing activities was approximately $380.89 million, compared to $319.84 million in the previous period, representing an increase of about 19.1%[52] - The net cash flow from investing activities was negative at approximately $380.89 million, worsening from a negative $215.46 million in the previous period[52] - Cash inflow from financing activities was approximately $416.41 million, down from $448.28 million, indicating a decrease of about 7.1%[52] - The net cash flow from financing activities was approximately $137.24 million, a decrease of about 38.9% from $224.92 million in the previous period[52] - The ending cash and cash equivalents balance was approximately $530.38 million, compared to $470.60 million in the previous period, reflecting an increase of about 12.7%[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,199,028,028.60, reflecting a growth of 4.03% from CNY 5,959,020,827.97 at the end of the previous year[5] - Total current liabilities were CNY 1,248,308,071.79, compared to CNY 1,484,098,044.10 previously[30] - The total liabilities increased to ¥3,258,533,476.71 from ¥3,156,510,196.83, showing a growth of approximately 3.23%[45] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96[30] - The company's short-term borrowings decreased to CNY 484,841,770.00 from CNY 613,389,696.81[30] Equity and Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.92% to CNY 2,940,494,551.89 from CNY 2,802,510,631.14 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, representing a growth of about 4.93%[45] - The company has a total of 31,026,544 shares held by its largest shareholder, Zhu Xiaoping[24] Expenses and Income - The company's inventory increased by 50.53% to CNY 485,459,996.95, up from CNY 322,510,850.58, indicating an increase in production stock[23] - The company's financial expenses decreased by 51.06% to CNY 8,759,306.14 from CNY 17,898,376.80, due to the capitalization of interest expenses[23] - The company received government subsidies amounting to CNY 9,070,325.65, a decrease of 30.31% compared to CNY 13,015,588.30 in the previous year[23] - The company reported an increase in investment income by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[23] - Research and development expenses rose to ¥61,517,923.07 from ¥56,659,055.19, reflecting an increase of about 8.73%[32] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[34] - The company reported a financial asset impairment loss of ¥-1,694,678.65, compared to ¥-1,250,138.89 in the previous period[34] - Other income decreased to ¥9,070,325.65 from ¥13,015,588.30, indicating a decline of about 30.38%[32]